

Dr Marc J. van de Vijver
Professor of Pathology
Dept. of Pathology
Academic Medical Center
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Tel.: +31 (20) 566 4100
Fax.: +31 (20) 566 9523
E-mail: m.j.vandevijver@amc.uva.nl



Academic degrees

MD, University of Amsterdam, Amsterdam, the Netherlands (1989)
PhD, University of Amsterdam, Amsterdam, the Netherlands (1989)
Professor of Pathology University of Amsterdam, Amsterdam, the Netherlands (2007)

Positions held

Head, Dept. of Pathology, Academic Medical Center, Amsterdam, the Netherlands (2007)
Head, Division of Diagnostic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands (1997–2007)
Head, Dept. of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands (1996–2007)
Pathologist, Staff member, Dept. of Pathology, Leiden University Medical Center, Leiden, the Netherlands (1993–2007)

Prizes and honors

Antoni van Leeuwenhoek award (1988)
Annick Griez award (1992)

Editorial board

Breast Cancer Research
Endocrine Related Cancer

Selected publications

Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ. Search for a gene expression signature of breast cancer local recurrence in young women. Clin Cancer Res 2012; 18(6):1704-15

- Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernardis R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell*. 2007; 12 (4): 395-402.
- Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). *Lancet Oncol*. 2007; 8 (12):1079-87. Erratum in: *Lancet Oncol*. 2008;9 (1): 10.
- Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. *Breast Cancer Res*. 2007; 9 (5): R65.
- Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. *Nat Genet*. 2006; 38 (4): 421-30.
- Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci U S A*. 2005; 102 (10): 3738-43.
- Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol*. 2005; 23 (15): 3331-42.
- van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernardis R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. 2002; 415 (6871): 530-6.
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernardis R. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med*. 2002; 347 (25): 1999-2009.
- van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse, R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. *N.Engl.J.Med*. 1988; 319 (19): 1239-45.

